Latest & greatest articles for ciprofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ciprofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ciprofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ciprofloxacin

1. Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials. (Full text)

Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials. The efficacy of inhaled ciprofloxacin agents in the treatment of patients with bronchiectasis is controversial. The objective of the study was to review systematically the efficacy of inhaled ciprofloxacin agents in patients with bronchiectasis.We searched PubMed, EMBASE, and Cochrane Library databases for randomized controlled trials (RCTs (...) ) evaluating inhaled ciprofloxacin agents among patients with bronchiectasis. Data were pooled using a meta-analysis technique.Two phase II and four phase III RCTs were included with a total of 1685 patients. Treatment durations of phase III studies were 48 weeks, while those of phase II studies were shorter. Pooled analysis of overall studies exhibited a statistically significant benefit of inhaled ciprofloxacin agents in three exacerbation outcome measures, including time to first exacerbation (hazard

2020 Therapeutic advances in respiratory disease PubMed abstract

2. Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies. (Full text)

Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies. Objectives: To perform a systematic review and meta-analysis of clinical studies to assess the comparative prophylactic effectiveness of fosfomycin trometamol (FMT) vs ciprofloxacin (CIP) in men who underwent transrectal ultrasonography-guided prostate needle biopsy (TRUS-PNB), as infectious complications are a major concern after TRUS (...) < 0.001) UTIs than CIP. Amongst all urine cultures, patients in the FMT arm also had a significantly lower prevalence of FQR and ESBL (E. coli or K. pneumoniae) microorganisms when compared to the CIP group (OR 0.25, 95% CI 0.12-0.21, P = 0.001; and OR 0.24, 95% CI 0.10-0.58, P = 0.001, respectively). Conclusions: Antibiotic prophylaxis with FMT before TRUS-PNB was associated with lower rates of infectious complications when compared to CIP. Abbreviations: CIP: ciprofloxacin; ESBL: extended-spectrum β

2020 Arab journal of urology PubMed abstract

3. Meningococcal disease and ciprofloxacin: PGD template

Meningococcal disease and ciprofloxacin: PGD template Meningococcal disease and ciprofloxacin: PGD template - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search The United Kingdom is leaving the European Union on 31 October 2019. Guidance Meningococcal disease and ciprofloxacin: PGD template Patient group direction (PGD) template to supply or administer ciprofloxacin for meningococcal disease clusters in educational (...) version of PGD template. 6 June 2018 Updated 'Meningococcal disease: PGD template for the supply or administration of ciprofloxacin'. 17 February 2017 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National Insurance number or credit card details. What were you doing? What went wrong? Send Help us improve GOV.UK To help us improve GOV.UK, we’d like to know

2019 Public Health England

4. Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis. (Abstract)

Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis. For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, prophylactic antibiotics are recommended as a standard regimen. This study aimed to assess the efficacy of norfloxacin (N), ciprofloxacin (C), trimethoprim-sulfamethoxazole (T-S), and rifaximin (R) in the prevention of SBP. We searched

2019 European journal of gastroenterology & hepatology

5. Diverticular disease: Ciprofloxacin

Diverticular disease: Ciprofloxacin Ciprofloxacin | Prescribing information | Diverticular disease | CKS | NICE Search CKS… Menu Ciprofloxacin Diverticular disease: Ciprofloxacin Last revised in December 2019 Ciprofloxacin Contraindications and cautions Do not prescribe ciprofloxacin to people: With a history of tendon disorders related to quinolone use. Who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic. Taking a corticosteroid — coadministration (...) could exacerbate fluoroquinolone-induced tendonitis and tendon rupture. Prescribe ciprofloxacin with caution to people with: Aortic aneurysm and/or aortic dissection, a family history of aneurysm disease, or with risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis). Epilepsy, or conditions that predispose to seizures

2019 NICE Clinical Knowledge Summaries

6. ciprofloxacin/fluocinolone (Cetraxal Plus)

ciprofloxacin/fluocinolone (Cetraxal Plus) ciprofloxacin/fluocinolone (Cetraxal Plus®) - All Wales Medicines Strategy Group Opens in new window Cymraeg Search Search Cymraeg Menu Search › › › ciprofloxacin/fluocinolone (Cetraxal Plus®) Following non-submission AWMSG advice Status: Not endorsed (Statement of Advice) In the absence of a submission from the holder of the marketing authorisation, ciprofloxacin/fluocinolone (Cetraxal Plus®) cannot be endorsed for use within NHS Wales (...) for the treatment in adults and in children aged 6 months and older for the following infections: Acute otitis externa (AOE); Acute otitis media in patients with tympanostomy tubes (AOMT) caused by ciprofloxacin susceptible microorganisms. Medicine details Medicine name ciprofloxacin/fluocinolone (Cetraxal Plus®) Formulation 3 mg per ml/0.25 mg per ml ear drops Reference number 4063 Indication Treatment in adults and in children aged 6 months and older for the following infections: Acute otitis externa (AOE

2019 All Wales Medicines Strategy Group

7. Quantifying the contribution of four resistance mechanisms to ciprofloxacin MIC in Escherichia coli: a systematic review. (Full text)

Quantifying the contribution of four resistance mechanisms to ciprofloxacin MIC in Escherichia coli: a systematic review. Reviews assessing the genetic basis of ciprofloxacin resistance in Escherichia coli have mostly been qualitative. However, to predict resistance phenotypes based on genotypic characteristics, it is essential to quantify the contribution of genotypic determinants to resistance.We performed a systematic review to assess the relative contribution of known genomic resistance (...) determinants to the MIC of ciprofloxacin in E. coli.PubMed and Web of Science were searched for English language studies that assessed ciprofloxacin MIC and presence or introduction of genetic determinants of ciprofloxacin resistance in E. coli. We included experimental and observational studies without time restrictions. Medians and ranges of MIC fold changes were calculated for individual resistance determinants and combinations thereof.We included 66 studies, describing 604 E. coli isolates that carried

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

8. Ciprofloxacin

Ciprofloxacin Top results for ciprofloxacin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ciprofloxacin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

9. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial (Full text)

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial Antibiotic prophylaxis for contacts of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal (...) meningitis.In this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care (the control arm), single-dose oral ciprofloxacin for household contacts within 24 hours of case notification, or village-wide distribution of ciprofloxacin within 72 hours of first case notification. The primary outcome was the overall AR of suspected meningitis after inclusion. A random

2018 EvidenceUpdates Controlled trial quality: predicted high PubMed abstract

10. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial (Abstract)

Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen. This study aims to investigate whether ciprofloxacin once weekly administration is not inferior to norfloxacin once daily administration for the prevention of SBP.This is an investigator-initiated open-label (...) randomized controlled trial conducted at seven tertiary hospitals in South Korea. Liver cirrhosis patients with ascites were screened, and enrolled in this randomized controlled trial if ascitic protein ≤1.5 g/dL or the presence of history of SBP. Ascitic polymorphonucleated cell count needed to be <250/mm3. Patients were randomly assigned into norfloxacin daily or ciprofloxacin weekly group, and followed-up for 12 months. Primary endpoint was the prevention of SBP.One hundred twenty-four patients met

2018 EvidenceUpdates

11. Ciprofloxacin ear drops (Cetraxal) - acute otitis externa

Ciprofloxacin ear drops (Cetraxal) - acute otitis externa Published 9 April 2018 Product Update: ciprofloxacin ear drops solution, single dose container 2mg/mL (Cetraxal ® ) SMC No 1320/18 Aspire Pharma Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) ciprofloxacin ear drops (Cetraxal ® ) are accepted for restricted use within NHS Scotland. Indication under review: treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. SMC restriction: when off-label or unlicensed ciprofloxacin formulations would otherwise be used. Ciprofloxacin eye drops (used off-label) or unlicensed ciprofloxacin ear drops have been in use in NHS Scotland for this indication

2018 Scottish Medicines Consortium

12. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (Full text)

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria.Patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in 14- or 28-day on/off treatment cycles for 48 weeks (...) . Primary end-points were time to first exacerbation and frequency of exacerbations. Enrolling countries and α level split (0.049 and 0.001 for 14- and 28-day cycles, respectively) differed from RESPIRE 1.Patients were randomised to ciprofloxacin DPI (14 days on/off (n=176) or 28 days on/off (n=171)) or placebo (14 days on/off (n=88) or 28 days on/off (n=86)). The exacerbation rate was low across treatment arms (mean±sd 0.6±0.9). Active treatment showed trends to prolonged time to first exacerbation

2018 EvidenceUpdates PubMed abstract

13. Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin (Full text)

Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin We have previously reported that supplementation of exogenous glutathione (GSH) promotes ciprofloxacin resistance in Escherichia coli by neutralizing antibiotic-induced oxidative stress and by enhancing the efflux of antibiotic. In the present study, we used a whole-genome microarray as a tool to analyze the system-level transcriptomic changes of E. coli (...) on exposure to GSH and/or ciprofloxacin. The microarray data revealed that GSH supplementation affects redox function, transport, acid shock, and virulence genes of E. coli. The data further highlighted the interplay of multiple underlying stress response pathways (including those associated with the genes mentioned above and DNA damage repair genes) at the core of GSH, offsetting the effect of ciprofloxacin in E. coli. The results of a large-scale validation of the transcriptomic data using reverse

2018 mSystems PubMed abstract

15. Pyelonephritis - acute: Ciprofloxacin

Pyelonephritis - acute: Ciprofloxacin Ciprofloxacin | Prescribing information | Pyelonephritis - acute | CKS | NICE Search CKS… Menu Ciprofloxacin Pyelonephritis - acute: Ciprofloxacin Last revised in March 2019 Ciprofloxacin Contraindications and cautions Do not prescribe ciprofloxacin to people: With a history of tendon disorders related to quinolone use. Who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic. Taking a corticosteroid (...) — coadministration could exacerbate fluoroquinolone-induced tendonitis and tendon rupture. Prescribe ciprofloxacin with caution to people with: Aortic aneurysm and/or aortic dissection, a family history of aneurysm disease, or with risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis). Epilepsy, or conditions that predispose

2018 NICE Clinical Knowledge Summaries

16. Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. (Full text)

Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. Multidrug-resistant Neisseria gonorrhoeae infections have been declared 1 of the top 3 urgent threats to public health. Approaches to combat resistance include targeted therapy with antibiotics previously thought to be ineffective, made possible by rapid molecular assays to predict susceptibility. Previous studies have associated (...) the gyrase A (gyrA) gene of N. gonorrhoeae with in vitro resistance to ciprofloxacin. We conducted a systematic review of studies comparing N. gonorrhoeae gyrA genotype results with conventional antimicrobial susceptibility testing results. We identified 31 studies meeting inclusion criteria, among which 7 different loci for mutations in the gyrA gene were identified, from 16 countries between the years of 1996 and 2016. We then performed a meta-analysis among those studies stratifying by use of real

2017 Sexually transmitted diseases PubMed abstract

17. Prostatitis - acute: Ciprofloxacin

Prostatitis - acute: Ciprofloxacin Ciprofloxacin | Prescribing information | Prostatitis - acute | CKS | NICE Search CKS… Menu Ciprofloxacin Prostatitis - acute: Ciprofloxacin Last revised in April 2019 Ciprofloxacin Cautions and contraindications Do not prescribe ciprofloxacin to people: With a history of tendon disorders related to quinolone use. Who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic. Taking a corticosteroid — coadministration could (...) exacerbate fluoroquinolone-induced tendonitis and tendon rupture. Prescribe ciprofloxacin with caution to people with: Aortic aneurysm and/or aortic dissection, a family history of aneurysm disease, or with risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis). Epilepsy, or conditions that predispose to seizures

2017 NICE Clinical Knowledge Summaries

18. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. (Full text)

Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. During the last decade the resistance rate of urinary Escherichia coli (E. coli) to fluoroquinolones such as ciprofloxacin has increased. Systematic reviews of studies investigating ciprofloxacin resistance in community- and hospital-acquired E. coli urinary tract infections (UTI) are absent. This study systematically reviewed (...) the literature and where appropriate, meta-analysed studies investigating ciprofloxacin resistance in community- and hospital-acquired E. coli UTIs.Observational studies published between 2004 and 2014 were identified through Medline, PubMed, Embase, Cochrane, Scopus and Cinahl searches. Overall and sub-group pooled estimates of ciprofloxacin resistance were evaluated using DerSimonian-Laird random-effects models. The I(2) statistic was calculated to demonstrate the degree of heterogeneity. Risk of bias

2015 BMC infectious diseases PubMed abstract

19. [Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: a systematic review with meta-analysis]. (Abstract)

[Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: a systematic review with meta-analysis]. A systematic review with meta-analysis of randomized controlled trials (RGT) on the efficacy and safety of ciprofloxacin in the treatment of acute or complicated urinary tract infections in adults. Primary outcomes were bacteriological eradication, clinical cure, bacterial resistance, and adverse event rates.Initially, 111 RGTs were identified. We excluded 81 (...) studies due to low quality methodology. An analysis of the remaining RGTs identified therapeutic equivalence of ciprofloxacin against other antimicrobials in terms of bacterial eradication and clinical cure at the end of treatment and in subsequent stages. The percentage of bacterial resistance was similar in both groups, while the percentage of related adverse events was significantly lower in the groups treated with ciprofloxacin.We conclude that ciprofloxacin is a safe and effective therapeutic

2015 Gaceta medica de Mexico

20. Meta-analysis of ciprofloxacin in treatment of Crohn's disease. (Full text)

Meta-analysis of ciprofloxacin in treatment of Crohn's disease. The aim of the present study was to evaluate the efficacy of ciprofloxacin (cipro) for the treatment of Crohn's disease (CD) through a meta-analysis of randomized controlled trials. The PubMed, Embase and Cochrane Library databases were searched up to May 2014, with no language restrictions, for randomized placebo-controlled trials. Additional references were obtained from the reviewed studies. Five studies were in accordance

2014 Biomedical reports PubMed abstract